Concepedia
Statistics
Publications
13
Citations
378
H-Index
12
Active since
2012
Affiliations
Queen's University Belfast(Current)
AstraZeneca (United Kingdom)
AstraZeneca (United States)
Almac (United Kingdom)
University of Sheffield
Mark Wappett is an author at Queen's University Belfast specializing in oncology, molecular oncology, and medicine.
Publications per year
2012–2024
Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett et al. · Clinical Cancer Research · 2014 · 75 citations
Medicine, Oncology, Pathology +17
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers
James Bradford, Mark Wappett, Garry Beran et al. · Oncotarget · 2016 · 43 citations · Full text
Medicine, Cancer Biology, Molecular Biology +17
Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
Jennifer S. Ferris, Margarita Espona‐Fiedler, Claudia Hamilton et al. · Cell Death Discovery · 2020 · 42 citations · Full text
Medicine, Oncology, Pharmacology +17
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib
James Bradford, Matthew R. Farren, Steve Powell et al. · PLoS ONE · 2013 · 35 citations · Full text
Life Sciences, Molecular Biology, Oncology +17
Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC
Molly A. Taylor, Mark Wappett, Oona Delpuech et al. · Oncogene · 2016 · 33 citations · Full text
Medicine, Cancer Biology, Oncology +17
1–5 of 13